Microscopic Colitis Clinical Trial
Official title:
Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis
This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.
This is an open-label single-arm trial to evaluate the efficacy of Rifaximin in patients with active microscopic colitis (MC). 10 subjects will be asked to take 500mg Rifaximin three times per day for 4 weeks. The primary endpoints will be histologic response and clinical remission (less than 3 stools per day and less than 1 watery stool per day within the prior 7 days. The secondary endpoint will be change of the MC Disease Activity Index (MCDAI). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05998174 -
Faecal Microbiota Transplantation for Microscopic Colitis
|
Early Phase 1 | |
Recruiting |
NCT05058131 -
Modulation of Intestinal Barrier Function and Inflammation Via Butyrate-promoting Dietary Fibre
|
N/A | |
Completed |
NCT02303132 -
Ussing Experiments to Evaluate the Role of Medication-induced Microscopic Colitis
|
N/A | |
Terminated |
NCT05579444 -
Systems Biology of Gastrointestinal and Related Diseases
|
||
Recruiting |
NCT06031064 -
External Validation of a Microscopic Colitis Clinical Scoring System in Patients With Chronic Watery Diarrhoea
|
||
Recruiting |
NCT06172647 -
Mucosa Adherent Intestinal Microbiome in Microscopic Colitis and Colorectal Cancer
|
||
Recruiting |
NCT03477032 -
FMT in Inflammatory Bowel Disease
|
||
Completed |
NCT03275467 -
Faecal Microbiota Transplantation in Patients With Microscopic Colitis
|
N/A | |
Completed |
NCT01928667 -
Case-Control Study to Identify Risk Factors for Microscopic Colitis
|
N/A | |
Completed |
NCT00180050 -
Budesonide Treatment for Lymphocytic Colitis
|
Phase 3 | |
Not yet recruiting |
NCT05915104 -
Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis
|
Phase 2 | |
Completed |
NCT00952952 -
Trial of Mesalamine for the Treatment of Active Microscopic Colitis
|
Phase 2/Phase 3 |